华大智造公告称，其全资子公司MGI R&D HK拟于2026年2月11日向SwissRockets出售剥离相关资产及 负债后的CGI 100%股权。交割时买方支付初始付款，交割后12个月完成最终付款。同时，MGI US LLC 将StandardMPS测序技术及通用测序技术有偿授权给SwissRockets，CGI将相关知识产权反向授权给 MGI。CGI 2024 - 2025年营收分别为2.87亿元、3.04亿元，2025年净利润亏损1.03亿元。本次交易不会对 公司主营业务和财务造成实质不利影响。 ...

（华大智造公告） (编辑：杨燕 林辰) 近日，华大智造发布公告称，公司全资子公司MGIR&DHK与SwissRockets签署了《股份购买协议》， 拟以约5000万美元的对价出售剥离相关资产及负债后的全资子公司CompleteGenomics,Inc.（CGI）100% 股权。交易价格最终将依据交割情况确定。此外，公司与SwissRockets还签署了《授权许可协议修正 案》，新增将StandardMPS测序技术及通用测序技术有偿授权给SwissRockets。 此次交易预计将为公司带来显著的直接收益和持续的现金流改善，剥离CGI将减少归属于该业务单元的 亏损，从而提升公司整体盈利能力和经营效率。公司合计可获得不低于1.2亿美元的授权许可费，其中 包括已收到的2000万美元的首付款和未来的里程碑付款。交易后，公司将继续主导CoolMPS测序技术在 亚太及大中华区的业务拓展，并通过授权模式间接参与北美市场，优化全球资源配置。 ...

春节假期期间贵金属和原油价格强势上行 业内称需警惕后市波动风险 马年春节假期期间，全球大宗商品市场走势分化，整体呈现贵金属领涨、能源板块强势的特征，其中纽 约商品交易所（COMEX）白银期货、黄金期货及布伦特原油期货、WTI原油期货涨幅显著，成为市场 关注的焦点，工业金属等其他品类则表现分化。业内人士表示，美伊地缘博弈、美国关税政策裁定等事 件影响贵金属与原油价格走势，白银库存紧张等基本面因素也为其上涨提供支撑。展望后市，受供应端 不确定性、需求季节性波动及宏观环境扰动等影响，大宗商品价格波动大概率加剧，贵金属与原油仍将 是市场波动的核心品种，需重点关注相关风险。（中国证券报） 马年春节假期现货白银大涨近17% 多国指数创新高 马年春节假期全球资本市场多数上涨，韩国、英国、法国等多国指数均创历史新高。特朗普关税进入迷 雾区，美伊冲突走向愈加悲观，国际金银、油价大涨，白银涨近17%。（智通财经） 481只去年收益告负基金年内业绩转正 Wind资讯数据显示，截至2月23日，今年以来已有481只去年收益告负的基金实现净值增长率转正，其 中19只基金的净值增长率差值均超20个百分点。从产品类型来看，以中长期纯债型基金 ...

Core Viewpoint - The company, Shenzhen BGI Genomics Co., Ltd., is selling its subsidiary Complete Genomics, Inc. for approximately $50 million to Swiss Rockets, while also adjusting its sequencing technology licensing agreements to enhance its financial position and operational efficiency [1][2]. Group 1: Transaction Details - The company announced the sale of 100% equity of its subsidiary Complete Genomics, Inc. to Swiss Rockets for about $50 million, with the final price subject to closing conditions [1]. - The transaction involves the separation of related assets and liabilities from the subsidiary MGI Tech R&D HONG KONG CO., LIMITED [1]. - A licensing agreement amendment allows Swiss Rockets exclusive rights to the StandardMPS sequencing technology and a general license for universal sequencing technology in the U.S. and Canada [1]. Group 2: Financial Impact - The transaction is expected to generate significant direct revenue and improve cash flow, with an estimated $50 million income from the equity sale [2]. - The company anticipates a reduction in annual losses associated with the divested business unit, thereby enhancing overall profitability and operational efficiency [2]. - The licensing arrangement will provide a tiered revenue share based on the future global net sales of the licensed products, contributing to stable long-term cash flow [2]. Group 3: Strategic Positioning - The company retains permanent, free, and irrevocable rights to use 205 patents held by CGI, ensuring the integrity of its technology system and business continuity [2]. - The company will continue to lead the CoolMPS sequencing technology in the Asia-Pacific and Greater China regions while expanding StandardMPS technology outside the U.S. and Canada [2]. - The company plans to sign supply agreements based on the commercialization progress of the counterpart, ensuring efficient utilization of existing production capacity and maintaining supply chain synergy [2].

证券代码：688114 证券简称：华大智造 公告编号：2026-007 深圳华大智造科技股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 深圳华大智造科技股份有限公司（以下简称"公司"）第二届董事会第二十次会议于2026年2月14日以现 场结合通讯方式举行。会议通知已于2026年2月13日以邮件方式发出。全体董事一致同意豁免本次会议 的通知时限。会议应到董事10人，实到董事10人。公司董事长汪建先生因公务不便主持，与会董事一致 推举董事牟峰先生为本次会议的主持人。公司高级管理人员列席了董事会会议。本次董事会会议的召 集、召开程序符合《中华人民共和国公司法》《公司章程》等有关规定的要求。经与会董事审议和表 决，会议形成决议如下： 二、董事会会议审议情况 （一）审议通过《关于出售子公司100%股权及调整CoolMPS测序技术〈授权许可协议〉的议案》 公司全资子公司MGI Tech R&D HONG KONG CO., LIMITED（以下简称"MGI R&D H ...

来源：证券时报e公司 人民财讯2月23日电，华大智造(688114)2月23日公告，公司全资子公司MGI Tech R&D HONG KONG CO., LIMITED（简称"MGI R&D HK"）与Swiss Rockets AG（简称"Swiss Rockets"）签署了《股份购买 协议》，拟将MGI R&D HK剥离相关资产及负债后的全资子公司Complete Genomics, Inc.（简称"CGI"） 100%股权以约5000万美元的对价出售给Swiss Rockets，最终交易价格以交割情况为准。另外，公司全 资子公司MGI US LLC、CGI与Swiss Rockets签署了《授权许可协议修正案》，拟在《CoolMPS授权许 可协议》基础上，新增将公司的StandardMPS测序技术及通用测序技术有偿授权给Swiss Rockets。 ...

华大智造公告称，公司第二届董事会第二十次会议审议通过出售子公司股权及调整许可协议议案。全资 子公司MGIR&DHK拟将剥离资产及负债后的全资子公司CGI 100%股权，以约5000万美元出售给 SwissRockets。同时，新增将StandardMPS测序技术及通用测序技术授权给对方。此外，CGI将205项专 利等授权给MGIUSLLC。该议案尚需股东会审议。会议还提请召开2026年第二次临时股东会，将于3月 12日在深圳召开。 ...

Core Insights - The company has signed a licensing agreement for the CoolMPS sequencing technology, which includes the transfer of related patents and revenue sharing with Swiss Rockets [1] Group 1: Licensing Agreement Details - The agreement involves the paid licensing of CoolMPS sequencing technology and related products to Swiss Rockets, which will receive exclusive rights outside the Asia-Pacific and Greater China regions [1] - The company expects to receive at least $120 million in licensing fees, including a non-refundable upfront payment of $20 million and milestone payments of $20 million [1] Group 2: Financial Impact - The upfront payment of $20 million will be recognized within the year, while the milestone payment will be made upon completion of technology transfer or by the end of 2026 [2] - Continuous royalty payments based on net sales of licensed products are expected to significantly improve the company's cash flow and profitability [2] Group 3: Strategic Focus and Market Expansion - The company aims to reduce overseas operational costs while focusing on high-end innovation and market expansion by transferring technology without engaging in product development [2] - The transaction allows the company to concentrate resources on its core technology and product development, enhancing overall resource utilization and operational efficiency [2] Group 4: Global Strategy and Market Position - The CoolMPS technology's overseas business development marks a new model for domestic high-end scientific instruments, leveraging local advantages of Swiss Rockets to accelerate global strategy [3] - The company retains autonomy in the Asia-Pacific and Greater China regions while expanding its international market presence, with international revenue accounting for over 30% [3] - Revenue projections for 2025-2027 are estimated at 3.585 billion, 4.184 billion, and 4.936 billion yuan, with corresponding net profits of 29 million, 104 million, and 219 million yuan [3]

Group 1: Key Developments in BaiLi TianHeng - BaiLi TianHeng (688506.SH) will receive a milestone payment of up to $250 million for its dual-target ADC (antibody-drug conjugate) BL-B01D1, following an initial payment of $800 million last year [1] - The ADC BL-B01D1 targets EGFR and HER3 and has a total potential transaction value of up to $8.4 billion, setting a record for single-drug licensing in the global ADC field [1] - The collaboration with Bristol-Myers Squibb (BMS) includes joint development and commercialization of BL-B01D1, with ongoing global Phase II/III clinical trials for various cancers [1] Group 2: Financial Performance and Implications - BaiLi TianHeng reported a revenue of 171 million yuan in the first half of the year, a year-on-year decline of 96.92%, with a net loss of 1.118 billion yuan [2] - The milestone payment is expected to contribute positively to BaiLi TianHeng's revenue amidst its current financial challenges [2] Group 3: Developments in BGI Genomics - BGI Genomics (688114.SH) announced a licensing agreement with SwissRockets for its CoolMPS sequencing technology, marking a significant step in global commercialization of core technology patents [2][4] - The agreement includes a total of at least $120 million in upfront, milestone, and royalty payments, with an initial non-refundable payment of $20 million [3] - BGI Genomics aims to monetize its technology without additional R&D investment, potentially improving its profitability and cash flow [4]

Group 1 - The company held its 17th meeting of the second board on October 12, 2025, with all 10 directors present, and the meeting was conducted in accordance with relevant laws and regulations [2][5][6] - The board approved the signing of a licensing agreement for the CoolMPS sequencing technology with Swiss Rockets AG, granting exclusive rights outside the Asia-Pacific and Greater China regions [3][9][11] - The company will receive a minimum of $120 million in licensing fees from the agreement, including a non-refundable upfront payment of $20 million and milestone payments [11][41] Group 2 - The company plans to acquire shared patents related to the CoolMPS sequencing technology and stLFR library construction technology from its affiliate, BGI Research Institute, to streamline intellectual property management [10][42] - The board's decision on the licensing agreement and patent acquisition will be submitted for approval at the upcoming shareholder meeting on October 28, 2025 [8][12][46] - The licensing agreement is expected to positively impact the company's future performance and enhance its global commercialization and profitability [12][41] Group 3 - Swiss Rockets AG, the counterparty in the licensing agreement, is a Swiss-based innovative enterprise focused on biotechnology, with a strong emphasis on oncology and infectious diseases [18][19] - The company has established a solid financial standing, with total assets of approximately 5.77 million Swiss francs and a net profit of -14.38 million Swiss francs for 2024 [19] - The agreement includes provisions for revenue sharing based on net sales of licensed products, with a tiered royalty structure [11][31] Group 4 - The company aims to leverage the licensing agreement to realize the value of its technology without additional R&D investment, thereby improving profitability and cash flow [41] - The acquisition of shared patents is intended to eliminate ownership barriers and allow the company to act as the sole rights holder for future licensing [42] - The board's review process included assessments from the audit committee, independent directors, and the supervisory board, all of which supported the transaction [43][45][47]